Abstract
Chemotherapy is one of reliable and proven methods of malignant tumor and blood diseases treatment but however the drug side effects (particularly cardiotoxicity) occur. More often cardiovascular complications connect with anthracyclines and related drugs (doxorubicin, daunorubicyn, epirubicyn, idarubicyn, mitoxantron) which usually used at medical scheme because of wide spectrum of action and high effectiveness prescription. Risk of cardiotoxicity formation and existing diseases progression increases according to drug dose, patient’s age, cardiovascular risk factors presence and cardiovascular diseases history. Material and methods . 88 patients with established non-Hodgkin’s lymphoma diagnosis were examined in order to assess cardiovascular system state and pathology nature – 33 patients before chemotherapy and 55 patients in the long-term follow-up period (one year after the start of chemotherapy). Results . It was found that antitumor drugs induced cardiotoxicity may manifest at the beginning of chemotherapy as well as following up period. The cardiac cameras dilation associated with the increase of NTproBNP serum content (N-terminal fragment of natriuretic peptide type B precursor) – the main biomarker of myocardial dysfunction has been revealed by instrumental research.
Highlights
It was found that antitumor drugs induced cardiotoxicity may manifest at the beginning of chemotherapy as well as following up period
The cardiac cameras dilation associated with the increase of NTproBNP serum content (N-terminal fragment of natriuretic peptide type B precursor) – the main biomarker of myocardial dysfunction has been revealed by instrumental research
Также обращает на себя внимание более низкая концентрация маркеров системного воспаления (СРБ, фибриноген) во 2-й группе пациентов, что, на наш взгляд, может отражать процессы угнетения иммунной системы на фоне основного заболевания и длительной ПХТ
Summary
It was found that antitumor drugs induced cardiotoxicity may manifest at the beginning of chemotherapy as well as following up period. Широко представлены работы по изучению кардиотоксического действия антрациклинов у больных, которые получали высокие суммарные дозы этих препаратов, превышающие пороговую величину, однако малоизученными остаются оценка изменений сердечно-сосудистой системы у пациентов, получавших небольшие суммарные дозы антрациклинов в динамике химиотерапии, а также взаимосвязь течения основного заболевания с морфометрическими показателями мио карда и показателями центральной гемодина мики [8]. Цель исследования – оценить состояние сер дечно-сосудистой системы и характер кардио васкулярной патологии у больных НХЛ при различной агрессивности процесса в дебюте заболевания и в отдаленном периоде после химио терапии.
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call